Backed by bullish positioning from 73 hedge funds and analyst expectations of 30.93% upside, Abbott Laboratories (NYSE:ABT) ranks among the top stocks to buy for financial stability.
Abbott Laboratories has drawn mixed analyst signals recently, with one firm seeing hidden value in a breakup scenario while another trimmed its outlook on broader sector concerns.
On June 17, 2026, Citi reiterated a “Buy” rating on Abbott Laboratories and argued that the company’s individual businesses may be worth more separately than under the current corporate structure. The firm’s sum-of-the-parts analysis implied a valuation range of $99 to $104 per share. Citi also said that easing headwinds and contributions from new products could help improve sentiment after the recent weakness in the stock.
That view followed a June 12, 2026, note from BofA analyst Travis Steed, who lowered the firm’s price target on Abbott Laboratories to $102 from $120 while maintaining a “Buy” rating. Steed cited continued signs of a softer utilization environment flagged by the firm’s services team, prompting a more conservative stance on 2027 medtech forecasts.
The analyst also incorporated a greater inflation impact into his outlook, expecting less room for margin expansion across the medical technology sector. As a result, BofA reduced 2027 estimates across several large-cap medtech names exposed to utilization trends and inflation pressures, with Abbott Laboratories among the companies affected by the broader revision.
Abbott Laboratories is a global healthcare company focused on the discovery, development, manufacture, and sale of a broad range of healthcare products.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.